Onesource Specialty Pharma Limited has informed the Exchange Update on Composite Scheme of Arrangement and Amalgamation (Merger by Absorption) amongstSteriscience Specialties Private Limited, Brooks Steriscience Limited, Steriscience Pte. Limited, Strides Pharma Services Private Limited and Onesource Specialty Pharma Limited and their respective shareholders (under section 230 to 232 read with section 234, section 52, section 66 of the Indian Companies Act and under section 210 read with section 212 of The Singapore Companies Act, 1967 and other applicable provisions of the Indian Companies Act, 2013, the Singapore Companies Act, 1967 and the rules framed thereunder ( Proposed Scheme )
ONESOURCE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Onesource Specialty Pharma has decided not to proceed with the proposed merger by absorption involving Steriscience Specialties, Brooks Steriscience, Steriscience Pte. Limited, and Strides Pharma Services. The Board deliberated on the transaction and concluded it was not in the best interest of stakeholders in its current form. The company had previously received in-principle approval for the scheme in February 2026, which was intended to bring SteriScience's facilities in Poland and Baroda under OneSource. The decision has been deferred and will be revisited after the companies deliver their FY28 guidance successfully.
The termination of this cross-border merger deal removes a key near-term growth catalyst for OneSource, likely creating uncertainty about the company's expansion strategy and near-term stock sentiment.